Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Lymphoma, T-Cell, Peripheral × ivarmacitinib × Clear all

Phase

Status

Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE 1 Lymphoma, T-Cell, Peripheral 1 Breast Neoplasms 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Azacitidine 2 tazemetostat 1 ivarmacitinib 1 duvelisib 1 Abatacept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05900089 2023-06-12

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Henan Cancer Hospital

Phase 1 Not yet recruiting

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡